Charles River Laboratories International, Inc. acquired privately-held Molecular Imaging Research, Inc. (d/b/a MIR Preclinical Services) for approximately $12.5 million in cash. Ann Arbor, Michigan-based MIR Preclinical Services (MIR) provides discovery services supported by extensive in vivo imaging capabilities to pharmaceutical and biotechnology clients.
MIR offers non-GLP (Good Laboratory Practice) preclinical efficacy testing services with expertise in the key therapeutic areas of oncology and inflammation. The key differentiator of MIR, according to the company, compared to traditional discovery service providers is the use of multiple modalities of state-of-the-art, in vivo imaging techniques. MIR applies high-throughput and imaging technologies, including preclinical positron emission tomography (PET), preclinical micro-computed tomography (CT), anatomical and functional magnetic resonance imaging (MRI), and bioluminescence and fluorescence biophotonic imaging. These imaging services permit noninvasive in situ and quantitative analysis of both efficacy and mechanism of action.
MIR will join Charles River Discovery Services, a provider of non-GLP pharmacology services to evaluate the efficacy of compounds. With the addition of MIR, Charles River now offers expertise in four key therapeutic areas including metabolic and cardiovascular diseases, oncology and inflammation, complemented by expanded in vivo imaging capabilities.
Release Date: September 15, 2008
Source: Charles River
Filed Under: Drug Discovery
